Excellent analysis Bedger. Makes complete sense. Thank you for articulating and providing detailed examples.
Appears OCC have have been going from strength to strength.
Be interesting to see next quarter sales to confirm the uptrend and it'll be useful if they could provide a split between Striate and Remplir.
With eyes towards Remplir FDA approval, the uptake locally can enable analysis on the anticipated introduction in the US.
Appreciate all your insights on this board and contribution to other stem cells company boards.
As disclosure, I have a sizable stake in MSB, OCC, PNV, VCEL and recently sold off CYP (may revisit at some stage).
OCC showing great promise.
VFM
OCC Trading, page-1693
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $76.49M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.5¢ | $44.20K | 119K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 93553 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 4500 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| OCC (ASX) Chart |